Precision BioSciences/$DTIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precision BioSciences
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Ticker
$DTIL
Sector
Primary listing
Employees
66
Headquarters
Website
DTIL Metrics
BasicAdvanced
$211m
-
-$2.62
1.31
-
Price and volume
Market cap
$211m
Beta
1.31
52-week high
$8.82
52-week low
$3.53
Average daily volume
483k
Financial strength
Current ratio
14.016
Quick ratio
13.563
Long term debt to equity
35.36
Total debt to equity
37.406
Interest coverage (TTM)
-28.36%
Profitability
EBITDA (TTM)
-37.739
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-96.73%
Operating margin (TTM)
-86.77%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-18.22%
Return on equity (TTM)
-70.93%
Valuation
Price to revenue (TTM)
3.024
Price to book
2.77
Price to tangible book (TTM)
2.82
Price to free cash flow (TTM)
-2.301
Free cash flow yield (TTM)
-43.46%
Free cash flow per share (TTM)
-3.555
Growth
Revenue change (TTM)
-11.87%
Earnings per share change (TTM)
-6.05%
3-year revenue growth (CAGR)
13.83%
3-year earnings per share growth (CAGR)
-56.79%
What the Analysts think about DTIL
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
DTIL Financial Performance
Revenues and expenses
DTIL Earnings Performance
Company profitability
DTIL News
AllArticlesVideos
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Business Wire·5 days ago
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Business Wire·1 month ago
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs